Skip to main navigation
Skip to search
Skip to main content
Sort by
Immunology and Microbiology
T-Helper Cell
100%
T Cell
93%
Human Immunodeficiency Virus 1
80%
CD28
77%
CD3 Antigen
56%
CD4
43%
Human immunodeficiency virus
37%
Interferon
25%
Gene Expression
22%
Infectious Disease
22%
Infection
22%
CD8
19%
CCR5
19%
Gene Transfer
19%
Macrophage
18%
ELISA
18%
Alemtuzumab
18%
Cytokine
16%
Epidermal Growth Factor
15%
Human Immunodeficiency Virus Infection
15%
Receptor Gene
15%
Squamous Cell Carcinoma Cell Line
15%
Allele
15%
Adenosine Deaminase
15%
Acquired Immune Deficiency Syndrome
15%
Growth Inhibition
15%
Cytotoxic T Cell
15%
Epitope
15%
HIV Type 1
15%
Systemic Lupus Erythematosus
15%
T Cell Depletion
15%
Immune Reconstitution
15%
Large Scale Production
15%
Hematopoiesis
15%
In Vitro
13%
T Cell Receptor
13%
CD4 Lymphocyte Count
10%
Virus
9%
Viral Load
9%
Peptides
8%
Replication
7%
Immunotherapy
7%
Lymphocyte
7%
Transgene
7%
Cell Line
7%
Enzyme-Linked Immunospot Assay
6%
Vaccinia virus
6%
B Cell
6%
Retrovirus Vector
5%
Secretion (Process)
5%
Medicine and Dentistry
Malignant Neoplasm
58%
Acetylsalicylic Acid
54%
Cancer Mortality
30%
T Cell
30%
Cancer Incidence
30%
Cancer Therapy
30%
Cancer
23%
Human immunodeficiency virus
19%
Gene Transfer
19%
Gene Therapy
18%
Cardiovascular Disease
18%
Hazard Ratio
17%
Randomized Controlled Trial
17%
Pemetrexed
15%
Skin Fibroblast
15%
Oncogene
15%
Cerebrospinal Fluid Cytology
15%
Genetics
15%
Meningeal Carcinomatosis
15%
Leishmaniasis
15%
Sodium Stibogluconate
15%
Prostate Cancer
15%
Apoplexy
15%
Cell Therapy
15%
Lymphocyte
11%
Infusion
9%
Cancer Treatment
8%
Neoplasm
8%
Transgene
7%
Placebo
7%
Low Drug Dose
7%
Cancer Types
6%
Infection
6%
Cytopenia
6%
Randomized Clinical Trials
6%
Retrovirus Vector
5%
Diseases
5%
Adverse Event
5%
Oncogene C Myc
5%
Li-Fraumeni Syndrome
5%
Disease Predisposition
5%
Ionizing Radiation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acquired Immune Deficiency Syndrome
34%
Human Immunodeficiency Virus Proteinase Inhibitor
30%
Acetylsalicylic Acid
30%
Cancer Incidence
30%
HIV
28%
Malignant Neoplasm
27%
Kaposi Sarcoma
22%
Diseases
19%
Randomized Controlled Trial
18%
Rapamycin
18%
Protein Kinase B
17%
Nelfinavir
17%
Maximum Tolerated Dose
16%
Solid Malignant Neoplasm
15%
Phase I Trials
15%
Bevacizumab
15%
Gene Delivery
15%
Non Small Cell Lung Cancer
15%
Cancer Mortality
15%
Sorafenib
15%
Adenosine Deaminase
15%
Pemetrexed
15%
Sodium Stibogluconate
15%
Leishmaniasis
15%
Systemic Lupus Erythematosus
15%
Neuroleptic Malignant Syndrome
15%
Colorectal Carcinoma
15%
Anti-Inflammatory Drug
15%
Adverse Event
13%
Infection
10%
Non-Steroidal Anti-Inflammatory Drug
8%
Ritonavir
8%
Clinical Trial
8%
CYP3A4
6%
Creatine Kinase
5%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
5%
Syndrome
5%
Droperidol
5%
Akinetic Mutism
5%
Prochlorperazine
5%
